Key result
Chronic ivabradine treatment lowered heart rate by 29% but did not improve left ventricular systolic performance or remodeling in middle-aged rats with post-myocardial infarction heart failure.
Why the study?
Does ivabradine improve left ventricular remodeling and systolic performance in middle-aged rats with post-MI heart failure?
Does ivabradine improve left ventricular remodeling and systolic performance in middle-aged rats with post-MI heart failure?
In a middle-aged rat model of post-MI heart failure, chronic ivabradine reduced heart rate but failed to improve LV systolic performance, with abrupt withdrawal worsening heart failure.
Does not support remodeling benefit from ivabradine in middle-aged post-MI HF; hypothesis-generating and requires validation in other models.
Background: A large myocardial infarction (MI) initiates progressive cardiac remodeling that leads to systolic heart failure (HF). Long-term heart rate reduction (HRR) induced by the I f current inhibitor ivabradine (IVA) ameliorates left ventricular (LV) remodeling and improves systolic performance in young post-MI rats. However, the beneficial effects of chronic IVA treatment in middle-aged rats remain to be determined. Methods: A large MI was induced in 12-month-old rats by left coronary artery ligation. Rats were treated with IVA via osmotic pumps intraperitoneal in a dose of 10.5 mg/kg/d (MI + IVA) and compared with MI and sham-operated animals 12 weeks after MI. Results: Heart rate in MI + IVA rats was on average 29% lower than that of rats in the MI group. Left ventricular remodeling was comparable between post-MI groups, although MI + IVA rats did not show the compensatory thickening of the noninfarcted myocardium. Chronic HRR had no effect on transverse cardiac myocyte size and capillary growth, but it reduced the collagen content in noninfarcted myocardium. Left ventricular systolic performance remained similarly impaired in MI and MI + IVA rats. Moreover, abrupt IVA withdrawal led to worsening HF and reduction of coronary reserve. Conclusion: Our data reveal that chronic IVA-induced HRR does not provide sustainable benefits for LV systolic performance in middle-aged rats with post-MI HF.
No takes yet. Share an insight, caveat, or question.
Dedkov et al. (2014) studied Postmyocardial infarction heart failure. Ivabradine vs. Untreated MI and sham-operated animals was evaluated on Left ventricular remodeling and systolic performance. Chronic ivabradine treatment lowered heart rate by 29% but did not improve left ventricular systolic performance or remodeling in middle-aged rats with post-myocardial infarction heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: